- Data obtained from the State Health Information Network for New York (SHIN-NY) and from hospital data requests

- Laboratory results from New York State Department of Health 

- Abstraction from hospital electronic medical records done by a team of nurses, doctors, and epidemiologists to record outcomes, illness and treatment details


Data collection for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydrochloroquine, or a combination

- Took a random sample of eligible patients, stratified by hospital

- 25 hospitals in New York City metropolitan area were selected by having a “high-volume” of COVID-19 cases, defined as 45 discharges during the sampling period

- Patients were eligible if admitted to one of these hospitals for at least 24 hours between March 15 and March 28, 2020 and tested positive for SARS-CoV-2

Sample selection for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination

- Patient demographics
- Preexisting conditions
- Initial vital signs
- Laboratory test results within 24 hours of admission
- Chest imaging
- Racial and ethnic classification 


Data/variables of interest for evaluating outcomes in hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination

- Sample selection
- Data collection
- Data/variables of interest
- Statistical analysis


University of Michigan - Ann Arbor

Amongst random sample of 1438 hospitalized, laboratory-confirmed COVID-19 cases across metropolitan New York City, in-hospital mortality was not significantly different for those treated with with hydroxychloroquine (Hazard ratio (HR)=1.08 [95% confidence interval (CI)= 0.63-1.85]), azithromycin (HR=0.56 [95% CI= 0.26-1.21]), or both (HR=1.35  [95% CI= 0.76-2.40]).

Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination

Methods for determining hazard ratio for in-hospital mortality amongst hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination

Learn Before

Learn After